As of today (2026-07-08), the Forward Annual Dividend Yield of Brooks Laboratories is 0.00%.
As of today (2026-07-08), the Trailing Annual Dividend Yield of Brooks Laboratories is 0.00%.
BOM:533543's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2 * Ranked among companies with meaningful Forward Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Brooks Laboratories Forward Dividend Yield % Related Terms
BOM:533543 vs ZTS, UTHR: Forward Dividend Yield % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Brooks Laboratories's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brooks Laboratories Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Brooks Laboratories's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Brooks Laboratories's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Brooks Laboratories (BOM:533543) has a Forward Dividend Yield % of 0.00% as of Jul. 08, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Brooks Laboratories and its competitors. According to the industry distribution chart, Brooks Laboratories ranks #999999 out of 505 companies in the Drug Manufacturers industry.
Is Brooks Laboratories' Forward Dividend Yield % too high?
Brooks Laboratories' current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Brooks Laboratories ranks #999999 out of 505 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Brooks Laboratories has a GF Score™ of 61/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Brooks Laboratories' Forward Dividend Yield % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Brooks Laboratories ranks #999999 out of 505 companies for Forward Dividend Yield %. This places Brooks Laboratories in the lower half of its industry. The industry median Forward Dividend Yield % is 2.00. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.00, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Brooks Laboratories and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Brooks Laboratories's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brooks Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Brooks Laboratories (BOM:533543) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹117.87, compared to a current price of ₹73.15 — trading 37.9% below its estimated fair value. The current Forward Dividend Yield % is 0.00%. Brooks Laboratories' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Brooks Laboratories (BOM:533543), the current Forward Dividend Yield % is 0.00% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Brooks Laboratories (BOM:533543) Overvalued in 2026?
Based on GuruFocus' analysis, Brooks Laboratories stock appears to be undervalued.
The current stock price of ₹73.15 is trading 37.9% below its estimated GF Value™ of ₹117.87.
GuruFocus considers Brooks Laboratories to be Significantly Undervalued.
Key valuation signals for BOM:533543:
Forward Dividend Yield %: 0.00%
GF Value™: ₹117.87 vs. price of ₹73.15 (37.9% below fair value)
No single metric tells the full story. See the BOM:533543 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Brooks Laboratories Ltd is a pharmaceutical manufacturer focused on developing and producing a broad range of generic medicines. Its key segments include injectables, tablets, and dry syrups, with product lines covering antibiotics such as beta-lactams and cephalosporins as well as general critical care injectables. The company operates manufacturing facilities compliant with international quality standards located in India, serving both domestic and international markets. Revenue is generated through contract manufacturing and sales of pharmaceutical formulations distributed broadly across regulated and semi-regulated international markets. The company has obtained regulatory certifications from multiple countries to comply with international standards for pharmaceutical manufacturing.
61GF Score
Get the complete analysis for BOM:533543
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:533543 has been successfully added to your 